PER-029-15尚未招募未知
A Phase 3 Randomized, Double-Blind Study of PF-06439535 plus Paclitaxel-Carboplatin and Bevacizumab plus Pacitaxel-Carboplatin for the first-line treatment of patients with advanced non-squamous non-small cell lung cancer.
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- PFIZER S.A.,
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patient eligibility should be reviewed and documented by an appropriate member of the investigator’s study team before patients are included in the study.
- •Patients must meet all of the following inclusion criteria to be eligible for enrollment into the
- •1. Male and female patients age ≥18 years of age, or ≥ age of consent in the region.
- •2. Newly diagnosed Stage IIIB or IV non-small cell lung cancer (according to Revised International System for Staging Lung Cancer criteria of 2010) or recurrent non-small cell lung cancer (NSCLC) for which they had not received chemotherapy for metastatic disease.
- •3. Histologically or cytologically confirmed diagnosis of predominately non-squamous
- •4. At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1). ...(See Printed Dossier)
排除标准
- •Patients presenting with any of the following will not be included in the study:
- •1. Small cell lung cancer (SCLC) or combination SCLC and NSCLC. Squamous-cell tumors and mixed adenosquamous carcinomas of predominantly squamous nature.
- •2. Evidence of a tumor that compresses or invades major blood vessels or tumor cavitation.
- •3. Known sensitizing EGFR mutations (for example, deletion 19 or L858R) or EML4-ALK translocation positive mutations.
- •4. History of other cancer within 5 years prior to screening for this study, with the exception of adequately treated ductal carcinoma in situ of the breast, cervical carcinoma in situ, or basal or squamous cell skin cancer.
- •5. Prior systemic therapy for metastatic disease. ...(See Printed Dossier)
研究者
相似试验
进行中（未招募）
1 期
A study to test if PF-06439535 plus Paclitaxel-Carboplatin compared to Bevacizumab plus Paclitaxel-Carboplatin is an effective treatment in patients with advanced non-squamous non-small cell lung cancer.Advanced non-squamous non-small cell lung cancer.MedDRA version: 18.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003878-16-SKPfizer Inc, 235 East 42nd Street, New York, NY 10017719
进行中（未招募）
1 期
A study to test if PF-06439535 plus Paclitaxel-Carboplatin compared to Bevacizumab plus Paclitaxel-Carboplatin is an effective treatment in patients with advanced non-squamous non-small cell lung cancer.EUCTR2014-003878-16-GRPfizer Inc, 235 East 42nd Street, New York, NY 10017798
进行中（未招募）
1 期
A study to test if PF-06439535 plus Paclitaxel-Carboplatin compared to Bevacizumab plus Paclitaxel-Carboplatin is an effective treatment in patients with advanced non-squamous non-small cell lung cancer.Advanced non-squamous non-small cell lung cancer.MedDRA version: 19.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003878-16-CZPfizer Inc710
进行中（未招募）
1 期
A study to test if PF-06439535 plus Paclitaxel-Carboplatin compared to Bevacizumab plus Paclitaxel-Carboplatin is an effective treatment inpatients with advanced non-squamous non-small cell lung cancerAdvanced non-squamous non-small cell lung cancerMedDRA version: 20.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003878-16-ITPFIZER INC798
进行中（未招募）
1 期
A study to test if PF-06439535 plus Paclitaxel-Carboplatin compared to Bevacizumab plus Paclitaxel-Carboplatin is an effective treatment in patients with advanced non-squamous non-small cell lung cancer.Advanced non-squamous non-small cell lung cancer.MedDRA version: 19.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003878-16-HRPfizer Inc, 235 East 42nd Street, New York, NY 10017719